期刊文献+

中药三叶青及其组方干预荷MFC胃癌小鼠调节性T细胞和相关细胞因子表达的研究 被引量:14

Experimental Study on Intervention of the Radix Tetrastigme and Its Formula to the Expression of Regulatory T Cells(Treg) and Related Cy-tokines of MFC Tumor bearing 615
下载PDF
导出
摘要 [目的]研究中药三叶青及其与人参、莪术配伍对荷MFC615小鼠的调节性T细胞和相关细胞因子表达的影响。[方法]皮下接种法建立小鼠前胃癌肿瘤动物模型,随机分为8组,分别为荷瘤未用药7d组、三叶青7d组、三叶青+人参7d组、三叶青+莪术7d组,荷瘤未用药14d组、三叶青14d组、三叶青+人参14d组、三叶青+莪术14d组,每组9只。设正常组18只为对照。接种7d后灌胃给药,每日1次,正常组及荷瘤未用药组不灌胃。观察不同时期平均肿瘤体积、小鼠死亡情况;给药7d后,处死7d组及一半正常组动物。给药14d后,处死剩余全部,取外周血、脾脏,流式细胞术测定外周血及脾脏淋巴细胞中Treg细胞比例,ELISA法测定血清COX-2、PGE2含量。[结果]①抑瘤率:三叶青组、三叶青+人参组、三叶青+莪术组抑瘤率分别为20.84%、32.26%、8.81%;②外周血Treg细胞比例:14d时,三叶青+人参组Treg比例明显低于荷瘤未用药组;③脾脏Treg比例:三叶青+人参组Treg比例14d较7d未明显升高;④血清COX-2、PGE2含量:14d时,三叶青+人参组COX-2、PGE2含量明显低于荷瘤未用药组。[结论]①抑瘤效果从高到低依次为:三叶青+人参、三叶青、三叶青+莪术;②三叶青+人参组14d给药效果优于7d;③三叶青与人参配伍可以显著降低荷瘤鼠脾脏及外周血Treg比例及血清中COX-2、PGE2含量,延缓肿瘤进展,逆转肿瘤免疫逃逸。 [Objective]Research on the radix tetrastigme(Sanyeqing) and its formula with ginseng(Renshen) or Curcuma wenyujin(Wen 'ezhu) effect on expression of regulatory T cells(Treg) and related cytokines of MFC tumor bearing 615 Mice.[Methods]MFC tumor bearing 615 Mice models were established by inoculated subcutaneously way,and were randomly divided into normal group,the 7 days control group,7 days radix tetrastigme group,7days radix tetrastigme+ginseng group and 7 days radix tetrastigme+Curcuma wenyujin groups,14 days control group,14 days radix tetrastigme group,14days radix tetrastigme +ginseng group,14 days radix tetrastigme +Curcuma wenyujin group,a normal group was set up as the control.7 days after inoculation,the treatment groups were begun to intragastric administration one time every day,the normal group and the control group were not treated.Record the mean tumor volume in different periods and the mortality;the groups were executed after administration 7 days and 14days;the flow cytometry and ELISA method were used to test.[Results]①Inhibition rate of tumor volume:tumor inhibition rate of radix tetrastigme group,radix tetrastigme+ginseng group,radix tetrastigme+Curcuma wenyujin group were 20.84%,32.26%,8.81%;②Treg ratio in peripheral blood:after medication for 14 days,the Treg ratio of the radix tetrastigme group and radix tetrastigme+ginseng group was significantly lower than the control group;③Treg ratio in spleen:there was no significant difference between the radix tetrastigme+ginseng medication 14 days and 7 days;④the serum COX-2 and PGE2 content:after medication for 14days,the radix tetrastigme +ginseng group was significantly lower than control group.[Conclusion] ① The order of antitumor effect of the three drug formula(fron high to low):Radix tetrastigme+ginseng group,Radix tetrastigme,Radix tetrastigme+Curcuma wenyujin;②The effect of Radix tetrastigme+ginseng group 14 days was better than 7 days;③Radix tetrastigme and ginseng formula can significantly reduce the spleen and peripheral blood Treg ratio and COX-2,of PGE2 content in serum of tumor-bearing mouse and delay tumor progression,reverse tumor immune escape.
出处 《浙江中医药大学学报》 CAS 2014年第6期676-681,共6页 Journal of Zhejiang Chinese Medical University
基金 浙江省自然科学基金资助项目(LY12H27012)~~
关键词 三叶青 人参 莪术 调节性T细胞 免疫逃逸 环氧化酶-2 前列腺素E2 Radix Tetrastigme ginseng Ezhu regulatory T cell immune evasion COX-2 PGE-2
  • 相关文献

参考文献15

  • 1Curiel TJ,Coukos G,Zou L. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival[J].Nature Medicine,2004,(09):942-949.
  • 2Viguier M,Lemaitre F,Verola O. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells[J].Journal of Immunology,2004,(02):1444-1453.
  • 3Petersen RP,Campa M J,Sperlazza J. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients[J].CANCER,2006,(12):2866-2872.
  • 4Woo E Y,Chu C S,Goletz T J. Regulatory CD4+ CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer[J].CANCER RESEARCH,2001.4766-4772.
  • 5Woo E Y,Chu C S,Goletz T J. Cutting edge:Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation[J].Immunology,2002.4272-4276.
  • 6Wolf AM,Wolf D,Steurer M. Increase of regulatory T cells in the peripheral blood of cancer patients[J].Clin Canc Res,2003.606-612.
  • 7Liyanage UK,Moore TT,Joo HG. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma[J].Immunology,2002.2756-2761.
  • 8邹静,刘斌,陈雪华,李宁丽,王利,查琼芳.肺癌患者外周血调节性T细胞检测的临床意义[J].诊断学理论与实践,2010,9(3):260-263. 被引量:4
  • 9Marshall NA,Christie LE,Munro LR. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma[J].Blood,2004.1755-1762.
  • 10Curiel TJ,Coukos G,zou L. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival[J].Nature Medicine,2004.942-949.

二级参考文献16

  • 1刘莉,丁乾,曹如波,王晶,姚军霞,黄士昂.恶性肿瘤患者外周血CD4^+ CD25^+调节T细胞的检测及其临床意义[J].临床肿瘤学杂志,2005,10(4):342-345. 被引量:16
  • 2Fontenot JD,Gavin MA,Rudensky AY.Foxp3 programs the development and function of CD4+CD25+regulatory T cells[J].Nat Immunol,2003,4(4):330-336.
  • 3Nakamura K,Kitani A,Strobor W.Cell contact-dependent immunosuppression by CD4(+)CD25(+)regulatory T cells is mediated by cell surface-bound transforming growth factor beta[J].J Exp Med,2001,194(5):629-644.
  • 4Born WK,Reardon CL,O'Brien RL.The funotion of gammadelta T cells in innate immunity[J].Curr Opin Immunol.2006,18(1):31-38.
  • 5Moser B,Brandes M.Gammadelta T cells:an alternative type of professional APC[J].Trends Immunol,2006,27(3):112-118.
  • 6Staveley-O'Carroll K,Sotomayor E,Montgomery J,et al.Induction of antigen-specific T cell anergy:An early event in the course of tumor progression[J].Proc Natl Acad Sci USA,1998,95(3):1178-1183.
  • 7Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains(CD25).Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J].J Immunol,1995.155(3):1151-1164.
  • 8Baecher-Allan C,Brown JA,Freeman GJ,et al.CD4+CD25high regulatory cells in human peripheral blood[J].J Immunol,2001,167(3):1245-1253.
  • 9Sakaguchi S.Regulatory T cells:key controllers of immunologic self-tolerance[J].Cell,2000,101(5):455-458.
  • 10Jones E,Dahm-Vicker M,Colsher D,et al.CD25+ regulatory T cells and tumor immunity[J].Immunol Lett,2003,85(2):141-143.

共引文献3

同被引文献267

引证文献14

二级引证文献141

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部